Overexpression of G100S mutation in PRKAG2 causes wolff-parkinson-white syndrome in zebrafish

Clinical Genetics

Volumn 86, Issue 3, 2014, Pages 287-291

  Zhang, B L ^a   Ye, Z ^a   Xu, R L ^a   You, X H ^a   Qin, Y W ^a   Wu, H ^a   Cao, J ^a   Zhang, J L ^a   Zheng, X ^a   Zhao, X X ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Mutation; PRKAG2 cardiac; Syndrome; Zebrafish

Indexed keywords

AMP ACTIVATED PROTEIN KINASE REGULATORY SUBUNIT GAMMA 2; GLYCOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; UNCLASSIFIED DRUG; PRKAG2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HEART VENTRICLE HYPERTROPHY; MISSENSE MUTATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; WOLFF PARKINSON WHITE SYNDROME; ZEBRA FISH; ANALYSIS OF VARIANCE; ANIMAL; GENE VECTOR; GENETICS; HISTOLOGY; HUMAN; METABOLISM; PERIODIC ACID SCHIFF STAIN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; TRANSGENE; TRANSGENIC ANIMAL; WESTERN BLOTTING;

DANIO RERIO;

AMP-ACTIVATED PROTEIN KINASES; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOTTING, WESTERN; GENETIC VECTORS; HISTOLOGICAL TECHNIQUES; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; PERIODIC ACID-SCHIFF REACTION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSGENES; WOLFF-PARKINSON-WHITE SYNDROME; ZEBRAFISH;

EID: 84907598182     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12267     Document Type: Article

References (19)

1. Ehtisham J, Watkins H. Is Wolff-Parkinson-White syndrome a genetic disease? J Cardiovasc Electrophysiol 2005: 16: 1258-1262.
2. Gollob MH. Glycogen storage disease as a unifying mechanism of disease in the PRKAG2 cardiac syndrome. Biochem Soc Trans 2003: 31: 228-231.
3. Gollob MH, Green MS, Tang AS et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001: 344: 1823-1831.
4. Gollob MH, Seger JJ, Gollob TN et al. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 2001: 104: 3030-3033.
5. Bayrak F, Komurcu-Bayrak E, Mutlu B, Kahveci G, Basaran Y, Erginel-Unaltuna N. Ventricular pre-excitation and cardiac hypertrophy mimicking hypertrophic cardiomyopathy in a Turkish family with a novel PRKAG2 mutation. Eur J Heart Fail 2006: 8: 712-715.
6. Arad M, Maron BJ, Gorham JM et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005: 352: 362-372.
7. Laforet P, Richard P, Said MA et al. A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis. Neuromuscul Disord 2006: 16: 178-182.
8. Murphy RT, Mogensen J, McGarry K et al. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol 2005: 45: 922-930.
9. Sternick EB, Oliva A, Magalhaes LP et al. Familial pseudo-Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol 2006: 17: 724-732.
10. Blair E, Redwood C, Ashrafian H et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001: 10: 1215-1220.
11. Arad M, Benson DW, Perez-Atayde AR et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 2002: 109: 357-362.
12. Xing Z. Familial conduction system abnormalities associated with ventricular pre-excitation and cardiac hypertrophy-A Department of Investigation and Analysis. Chin J Cardiol 2007: 35: 258-259.
13. Kim E, Lee SH, Lee KS et al. AMPK gamma2 subunit gene PRKAG2 polymorphism associated with cognitive impairment as well as diabetes in old age. Psychoneuroendocrinology 2012: 37: 358-365.
14. Lang T, Yu L, Tu Q et al. Molecular cloning, genomic organization, and mapping of PRKAG2: a heart abundant gamma2 subunit of 5'-AMP-activated protein kinase, to human chromosome 7q36. Genomics 2000: 70: 258-263.
15. Sidhu JS, Rajawat YS, Rami TG et al. Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. Circulation 2005: 111: 21-29.
16. Scott JW, Hawley SA, Green KA et al. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest 2004: 113: 274-284.
17. Arad M, Moskowitz IP, Patel VV et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 2003: 107: 2850-2856.
18. Banerjee SK, Ramani R, Saba S et al. A PRKAG2 mutation causes biphasic changes in myocardial AMPK activity and does not protect against ischemia. Biochem Biophys Res Commun 2007: 360: 381-387.
19. Verloes A, Massin M, Lombet J et al. Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency. Delineation of a neonatal form. Am J Med Genet 1997: 72: 135-142.